Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GSK971086 · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| placebo | DRUG | - |
| GSK971086 | DRUG | - |
Inclusion Criteria: * Males between 18 and 50 years of age (inclusive), at the time of signing the informed consent form. * Healthy, as determined by the Investigator, based on medical evaluations performed during the Screening Period including medical history, physical examination, clinical labora...
GSK971086 is an investigational small molecule being studied in healthy subjects and in the context of androgen deficiency. It is in Phase 1 clinical development for endocrine-related conditions. The drug is not approved and remains under investigation.
GSK971086 is being developed by GSK plc, a global biopharma company listed on the stock exchange under the ticker GSK. The company is conducting clinical trials to evaluate the safety, tolerability, and blood levels of this investigational drug.
GSK971086 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. Its safety and efficacy are still being evaluated in early-stage clinical trials.
GSK971086 has one completed Phase 1 clinical trial, identified as NCT00540553. This study tested the safety, tolerability, and blood levels of GSK971086 after a single dose and after 7 days of dosing in healthy adult males. The trial enrolled 126 participants in the United States.
No alternative names for GSK971086 have been disclosed. The drug is identified solely by its code name GSK971086 in clinical trial registries and by its developer, GSK plc.